Physician profile
Ute Gallert
NPI 1417204355
$4,711.35
in general payments reported to CMS, 2019-2025
31 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,137 · 2022: $1,386 · 2023: $1,480 · 2024: $574 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,189.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $661.12 | 2021-2024 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $576.42 | 2021-2024 | |
| Lilly USA, LLC | $563.78 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $529.69 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $463.23 | 2021-2024 | Epclusa |
| Abbvie INC. | $339.78 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $146.71 | 2022-2024 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Biohaven Pharmaceutical Holding Company LTD. | $141.55 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $135.28 | 2021 | |
| Janssen Pharmaceuticals, INC | $130.52 | 2022-2023 | Spravato |
| Otsuka America Pharmaceutical, INC. | $120.19 | 2022-2023 | Rexulti |
| Astellas Pharma US INC | $117.22 | 2022-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $101.95 | 2025 | |
| Alkermes, INC. | $90.99 | 2022-2023 | Vivitrol |
| Teva Pharmaceuticals USA, INC. | $81.42 | 2022-2023 | Austedo, Austedo Xr |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $80.39 | 2022-2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $68.56 | 2021-2024 | Airsupra |
| Therapeuticsmd, INC. | $45.82 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.77 | 2021-2022 | |
| Vbi Vaccine (Delaware) INC. | $38.33 | 2023 | Prehevbrio |
| Exact Sciences Corporation | $33.26 | 2023-2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $29.24 | 2022-2023 | Eliquis |
| Abbott Laboratories | $24.60 | 2021 | |
| Grifols USA, LLC | $23.30 | 2024 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $21.98 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.26 | 2022 | |
| Shield Therapeutics INC | $18.99 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.98 | 2023 | Trintellix |
| Dexcom, INC. | $18.78 | 2024 | Dexcom G6 Transmitter |
| Agile Therapeutics, INC. | $17.61 | 2021 | |
| Cequr Corporation | $11.63 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ute Gallert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.